Simultaneous disease detection system method and devices
US-12092629-B2 · Sep 17, 2024 · US
US9687176B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9687176-B2 |
| Application number | US-201213448095-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 16, 2012 |
| Priority date | Oct 16, 2008 |
| Publication date | Jun 27, 2017 |
| Grant date | Jun 27, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure concerns improved capabilities for evaluating pulmonary arterial hypertension (PAH). A system and method of evaluating PAH in a subject may include measuring end tidal partial pressure of exhaled carbon dioxide in the subject, wherein the measurement is made orally using described systems or devices. Integrated sensors enable the measurement and characterization of other respiratory gas components, some of which may be indicative of disease. The system and method can be used to monitor a course of treatment for PAH.
Opening claim text (preview).
What is claimed is: 1. A method for determining whether or not additional medical tests need to be conducted for a diagnosis of a pulmonary arterial hypertension condition in a patient, comprising the steps of: a) measuring end tidal carbon dioxide (EtCO2) of each of a plurality of oral expirations from the patient at rest with a system comprising: i) a housing; ii) a carbon dioxide analyzer located at least partially within the housing and adapted to measure the partial pressure of carbon dioxide in a composite gas; iii) a conduit adapted to transfer an expiration from the patient's mouth to the carbon dioxide analyzer; iv) a data transmitter adapted to transmit data from the carbon dioxide analyzer to a processor, the processor being located remotely from the housing and having a memory operably associated therewith; v) a range of carbon dioxide partial pressure values stored in the memory; and vi) an indicator adapted to respond to a signal from the processor to provide an output in a human cognizable format; b) calculating a composite EtCO2 value for the plurality of oral expirations at rest; c) comparing the composite EtCO2 value to the range of carbon dioxide partial pressure values stored in the memory of the system; d) generating a first signal based upon the comparison in step (c), the first signal indicative of whether or not additional medical tests needs to be conducted for the diagnosis of pulmonary arterial hypertension, wherein a lower range of the composite EtCO2 value is indicative of pulmonary arterial hypertension; and e) transmitting the first signal to the indicator of the system. 2. The method of claim 1 , wherein each of the plurality of oral expirations from the patient are captured using a tube placed in a mouth of the patient. 3. The method of claim 1 , further comprising instructing the patient to breathe tidally into a plastic tube inserted into a mouth of the patient. 4. The method of claim 1 , further comprising calibrating the carbon dioxide analyzer for a precision of ±2 mm Hg up to 38 mm Hg for a partial pressure of carbon dioxide. 5. The method of claim 1 , further comprising calibrating the carbon dioxide analyzer for a precision of ±0.08% for every 1 mm Hg over 40 mm Hg for a partial pressure of carbon dioxide. 6. The method of claim 1 , further comprising administering a 6-minute walking distance test (6MWT) check to at least one patient for further diagnosis of pulmonary arterial hypertension; and diagnosing pulmonary arterial hypertension when the EtCO2 does not increase after the 6MWT check. 7. The method of claim 6 , further comprising administering the 6MWT after the at least one patient has received a therapy for the pulmonary arterial hypertension. 8. A method for determining whether or not additional medical tests need to be conducted for a diagnosis of a pulmonary arterial hypertension condition in a patient, comprising the steps of: a) measuring end tidal carbon dioxide (EtCO2) of each of a plurality of oral expirations from the patient at rest with a system comprising: i) a housing; ii) a carbon dioxide analyzer located at least partially within the housing and adapted to measure the partial pressure of carbon dioxide in a composite gas; iii) a conduit adapted to transfer an expiration from the patient's mouth to the carbon dioxide analyzer; iv) a data transmitter adapted to transmit data from the carbon dioxide analyzer to a processor, the processor being located remotely from the housing and having a memory operably associated therewith; v) a range of carbon dioxide partial pressure values stored in the memory; and vi) an indicator adapted to respond to a signal from the processor to provide an output in a human cognizable format; b) calculating a composite EtCO2 value for the plurality of oral expirations at rest; c) comparing the composite EtCO2 value to the range of carbon dioxide partial pressure values stored in the memory of the system; d) generating a first signal based upon the comparison in step (c), the first signal indicative of whether or not additional medical tests needs to be conducted for the diagnosis of pulmonary arterial hypertension, wherein a lower range of the composite EtCO2 value is indicative of pulmonary arterial hypertension and a higher range of the composite EtCO2 value is indicative of pulmonary venous hypertension; and e) transmitting the first signal to the indicator of the system. 9. A method for determining whether or not additional medical tests need to be conducted for a diagnosis of a pulmonary arterial hypertension condition in a patient, comprising the steps of: a) measuring end tidal carbon dioxide (EtCO2) of each of a plurality of oral expirations from the patient at rest with a device comprising: i) a housing; ii) a carbon dioxide analyzer located at least partially within the housing and adapted to measure the partial pressure of carbon dioxide in a composite gas; iii) a conduit adapted to transfer an expiration from the patient's mouth to the carbon dioxide analyzer; iv) a first processor located within the housing and having a memory operably associated therewith; v) a range of carbon dioxide partial pressure values stored in the memory; and vi) an indicator adapted to respond to a signal from the processor to provide an output in a human cognizable format; b) calculating a composite EtCO2 value for the plurality of oral expirations at rest c) comparing the composite EtCO2 value to the range of carbon dioxide partial pressure values stored in the memory of the device; d) generating a first signal based upon the comparison in step (c), the first signal indicative of whether or not additional medical tests needs to be conducted for the diagnosis of pulmonary arterial hypertension, wherein a lower range of the composite EtCO2 value is indicative of pulmonary arterial hypertension; and e) transmitting the first signal to the indicator of the device. 10. The method of claim 9 , wherein each of the plurality of oral expirations from the patient are captured using a tube placed in a mouth of the patient. 11. The method of claim 9 , further comprising instructing the patient to breathe tidally into a plastic tube inserted into a mouth of the patient. 12. The method of claim 9 , further comprising calibrating the carbon dioxide analyzer for a precision of ±2 mm Hg up to 38 mm Hg for a partial pressure of carbon dioxide. 13. The method of claim 9 , further comprising calibrating the carbon dioxide analyzer for a precision of ±0.08% for every 1 mm Hg over 40 mm Hg for a partial pressure of carbon dioxide. 14. The method of claim 9 , further comprising administering a 6-minute walking distance test (6MWT) check to at least one patient for further diagnosis of pulmonary arterial hypertension; and diagnosing pulmonary arterial hypertension when the EtCO2 does not increase after the 6MWT check. 15. the method of claim 14 , further comprising administering the 6MWT after the at least one patient has received a therapy for the pulmonary arterial hypertension. 16. A method for determining whether or not additional medical tests need to be conducted for a diagnosis of a pulmonary arterial hypertension condition in a patient, comprising the steps of: a) measuring end tidal carbon dioxide (EtCO2) of each of a plurality of oral expirations from the patient at rest with a device comprising: i) a housing; ii) a carbon dioxide analyzer located at least partially within the housing and adapted to measure the partial pressure of carbon dioxide in a composite gas; iii) a condu
Devices for facilitating collection of breath or for directing breath into or through measuring devices · CPC title
Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath (A61B5/083, A61B5/091 take precedence) · CPC title
Measuring rate of CO2 production · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.